Morgan Stanley’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.04M | Sell |
43,239
-11,092
| -20% | -$524K | ﹤0.01% | 4687 |
|
|
2025
Q1 | $2.12M | Buy |
54,331
+7,187
| +15% | +$281K | ﹤0.01% | 4569 |
|
|
2024
Q4 | $2.55M | Sell |
47,144
-83,454
| -64% | -$4.52M | ﹤0.01% | 4536 |
|
|
2024
Q3 | $6.58M | Buy |
130,598
+61,571
| +89% | +$3.1M | ﹤0.01% | 3744 |
|
|
2024
Q2 | $3.04M | Sell |
69,027
-160,155
| -70% | -$7.04M | ﹤0.01% | 4276 |
|
|
2024
Q1 | $11.5M | Buy |
229,182
+96,154
| +72% | +$4.83M | ﹤0.01% | 3230 |
|
|
2023
Q4 | $8.03M | Buy |
133,028
+123,577
| +1,308% | +$7.46M | ﹤0.01% | 4081 |
|
|
2023
Q3 | $539K | Sell |
9,451
-149,974
| -94% | -$8.55M | ﹤0.01% | 5136 |
|
|
2023
Q2 | $8.13M | Buy |
159,425
+126,906
| +390% | +$6.47M | ﹤0.01% | 3359 |
|
|
2023
Q1 | $696K | Buy |
32,519
+5,154
| +19% | +$110K | ﹤0.01% | 5065 |
|
|
2022
Q4 | $287K | Buy |
27,365
+24,265
| +783% | +$255K | ﹤0.01% | 5511 |
|
|
2022
Q3 | $24K | Buy |
+3,100
| New | +$24K | ﹤0.01% | 6715 |
|
|
2022
Q1 | – | Sell |
-13,449
| Closed | -$133K | – | 8057 |
|
|
2021
Q4 | $133K | Hold |
13,449
| – | – | ﹤0.01% | 6278 |
|
|
2021
Q3 | $132K | Buy |
13,449
+7,549
| +128% | +$74.1K | ﹤0.01% | 6215 |
|
|
2021
Q2 | $61K | Sell |
5,900
-1
| -0% | -$10 | ﹤0.01% | 6587 |
|
|
2021
Q1 | $60K | Buy |
5,901
+5,900
| +590,000% | +$60K | ﹤0.01% | 6273 |
|
|
2020
Q4 | $0 | Buy |
+1
| New | – | ﹤0.01% | 7076 |
|